I do hame some basic understanding of the speciality chemical industry and yields are problematic. Some products can be scaled up easily to large scale manufacture. Some can be scaled up to medium size manufacture. And some don't really leave the labs because its impossible to scale them up.
*Then the onus was on AZ not to assure they would deliver the amounts they announced.
The scale-up of production was used in the first quarter. They were millions and millions of the numbers AZ said they would produce and deliver.
The reason was ramping up the lab capacity, but AZ gave huge assurance it would be on target with the catch up amounts this was excepted by all EU countries. It was to be expected was what I was told by my management
Then AZ announced last March they would not have the second quarter allocation let alone the catch supplies.
AZ are causing these issues. The only consistency AZ have given is to fail to deliver.
This is a multi-billion dollar business, which is playing games because I feel they are not making profits on the vaccine.*